208 related articles for article (PubMed ID: 28719598)
1. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Rafaniello C; Sessa M; Bernardi FF; Pozzi M; Cheli S; Cattaneo D; Baldelli S; Molteni M; Bernardini R; Rossi F; Clementi E; Bravaccio C; Radice S; Capuano A
Pharmacogenomics J; 2018 May; 18(3):422-430. PubMed ID: 28719598
[TBL] [Abstract][Full Text] [Related]
2. Genetic Variants in the
Morau MV; Seguin CS; Visacri MB; Pincinato EC; Moriel P
Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790220
[TBL] [Abstract][Full Text] [Related]
3. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
Chen YR; Yu X; Xu LM; Mei J; Tian ML; Xu M; Jin QY; Ye LB; Yang SX
Xenobiotica; 2024 Jan; 54(1):38-44. PubMed ID: 38085693
[TBL] [Abstract][Full Text] [Related]
4. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
Beunk L; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Risselada A; Rongen GAPJM; van Schaik RHN; Swen JJ; Touw D; van Westrhenen R; Deneer VHM; van der Weide J
Eur J Hum Genet; 2024 Mar; 32(3):278-285. PubMed ID: 37002327
[TBL] [Abstract][Full Text] [Related]
5. Association of ABCG2 Polymorphisms on Triple Negative Breast Cancer (TNBC) Susceptibility Risk.
Hao Ing Y; Md Salleh MS; Yahya MM; Ankathil R; Abdul Aziz AA
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3891-3897. PubMed ID: 38019248
[TBL] [Abstract][Full Text] [Related]
6. Effects of
Yang Y; Liu W; Wu R
Heliyon; 2024 Apr; 10(7):e28832. PubMed ID: 38576571
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.
Solmi M; Murru A; Pacchiarotti I; Undurraga J; Veronese N; Fornaro M; Stubbs B; Monaco F; Vieta E; Seeman MV; Correll CU; Carvalho AF
Ther Clin Risk Manag; 2017; 13():757-777. PubMed ID: 28721057
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents.
Ceylan MF; Erdogan B; Tural Hesapcioglu S; Cop E
Clin Drug Investig; 2017 Oct; 37(10):947-956. PubMed ID: 28726075
[TBL] [Abstract][Full Text] [Related]
9. A case of frontotemporal dementia with sexual disinhibition controlled by aripiprazole.
Nomoto H; Matsubara Y; Ichimiya Y; Arai H
Psychogeriatrics; 2017 Nov; 17(6):509-510. PubMed ID: 28745408
[No Abstract] [Full Text] [Related]
10. Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics.
McConnell SA; Desai DN; Faldu SP; Hard ML; Wehr AY; Weiden PJ; von Moltke L
Neuropsychiatr Dis Treat; 2017; 13():1815-1816. PubMed ID: 28744131
[No Abstract] [Full Text] [Related]
11. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.
Zhu Y; Krause M; Huhn M; Rothe P; Schneider-Thoma J; Chaimani A; Li C; Davis JM; Leucht S
Lancet Psychiatry; 2017 Sep; 4(9):694-705. PubMed ID: 28736102
[TBL] [Abstract][Full Text] [Related]
12. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials.
Corponi F; Serretti A; Montgomery S; Fabbri C
Int Clin Psychopharmacol; 2017 Nov; 32(6):309-318. PubMed ID: 28727644
[TBL] [Abstract][Full Text] [Related]
13. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
[TBL] [Abstract][Full Text] [Related]
14. A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder.
Findling RL; Youngstrom EA; Rowles BM; Deyling E; Lingler J; Stansbrey RJ; McVoy M; Lytle S; Calabrese JR; McNamara NK
J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):864-874. PubMed ID: 28759262
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Storelli F; Matthey A; Lenglet S; Thomas A; Desmeules J; Daali Y
Clin Pharmacol Ther; 2018 Jul; 104(1):148-157. PubMed ID: 28940476
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study.
Pringsheim T; Ho J; Sarna JR; Hammer T; Patten S
J Clin Psychopharmacol; 2017 Oct; 37(5):498-504. PubMed ID: 28816926
[TBL] [Abstract][Full Text] [Related]
17. Prodrugs - Recent approvals and a glimpse of the pipeline.
Rautio J; Kärkkäinen J; Sloan KB
Eur J Pharm Sci; 2017 Nov; 109():146-161. PubMed ID: 28782609
[TBL] [Abstract][Full Text] [Related]
18. Delirium in hospitalized patients: Risks and benefits of antipsychotics.
Thom RP; Mock CK; Teslyar P
Cleve Clin J Med; 2017 Aug; 84(8):616-622. PubMed ID: 28806160
[TBL] [Abstract][Full Text] [Related]
19. QT and QTc in Male Patients with Psychotic Disorders Treated with Atypical Neuroleptics.
Miniati M; Simoncini M; Vanelli F; Franceschini C; Massimetti G; Carmassi C; Dell'Osso L
ScientificWorldJournal; 2017; 2017():1951628. PubMed ID: 28785719
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?
Lertxundi U; Hernandez R; Medrano J; Domingo-Echaburu S; Garcia M; Aguirre C
Int Clin Psychopharmacol; 2018 Jan; 33(1):56-58. PubMed ID: 28777129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
